This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study
Blood Cancer Journal Open Access 09 December 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID . Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93: 3678–3684.
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR . Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.
Putti MC, Rondelli R, Cocito MG, Arico M, Sainati L, Conter V, Guglielmi C, Cantu-Rajnoldi A, Consolini R, Pession A, Zanesco L, Masera G, Biondi A, Basso G . Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88–91 studies. Blood 1998; 92: 795–801.
Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J . Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 1993; 53: 3336–3342.
Zwaan ChM, Kaspers GJL, Pieters R, Ramakers-Van Woerden NL, Den Boer ML, Wnsche R, Rottier MMA, HΩhlen K, Van Wering ER, Janka-Schaub GE, Creutzig U, Veerman AJP . Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB-types and comparison with acute lymphoblastic leukemia. Blood 2000; 96: 2879–2886.
Bernt KM, Lode HN, Hagemeier C, Gaedicke K, Wrasidlo W . CD19 targeted calicheamicin is effective against high risk ALL (abstract). Blood 2000; 96: 467a.
Acknowledgements
The authors wish to thank Wyeth Pharmaceuticals (St Davids, PA, USA) for providing us with calicheamicin to perform the cellular resistance studies described here. This study was financially supported by the ‘Landelijke Vereniging van Crematoria’, Eindhoven, The Netherlands, and performed in the setting of the ‘International BFM Study Group’, chaired by M Schrappe, Hannover, Germany. The authors wish to thank the Dutch Childhood Leukemia Study Group who provided us with additional samples for cellular drug resistance testing as well as with cell biological and clinical data. One of the authors (JF) is employed by a company (Wyeth Pharmaceuticals) whose product was studied in the present work.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zwaan, C., Reinhardt, D., Jürgens, H. et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 17, 468–470 (2003). https://doi.org/10.1038/sj.leu.2402749
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402749
This article is cited by
-
Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study
Blood Cancer Journal (2016)
-
Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions
Drugs (2013)
-
The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
Leukemia (2012)
-
Application of immunotherapy in pediatric leukemia
Current Hematologic Malignancy Reports (2009)
-
Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
International Journal of Hematology (2008)